Assyro AI

Orange Book product · Brand (NDA)

ZYKADIA

CERITINIB

Brand (NDA)NDA 205755DISCN NOVARTIS

At a glance

Apr 29, 2014

Approved

Brand (NDA)

Application

Not listed

TE code

7

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Apr 29, 2014

    12 yr 4 mo ago

  2. Patent 7893074 expires

    Listed drug substance patent expiration.

    Apr 25, 2026

    2 mo ago

  3. Today

  4. Patent 8377921 expires

    Listed method-of-use patent (U-1179) expiration.

    Nov 20, 2027

    in 1 yr 5 mo

  5. Patent 8399450 expires

    Listed drug substance patent expiration.

    Nov 20, 2027

    in 1 yr 5 mo

  6. Patent 7964592 expires

    Listed drug substance patent expiration.

    Apr 29, 2028

    in 1 yr 11 mo

  7. Patent 8039479 expires

    Listed drug substance patent expiration.

    Jun 29, 2030

    in 4 yr 1 mo

  8. Patent 9309229 expires

    Listed drug substance patent expiration.

    Jan 18, 2032

    in 5 yr 8 mo

  9. Patent 8703787 expires

    Listed method-of-use patent (U-1179) expiration.

    Feb 02, 2032

    in 5 yr 8 mo

Pharmaceutical detail

Active ingredient

CERITINIB

Strength

150MG

Dosage form

CAPSULE

Route

ORAL

TE code

Not listed

Application

NDA 205755

Product number

001

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (7)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7893074Apr 25, 20262 mo ago
SubstanceProduct
8377921Nov 20, 2027in 1 yr 5 mo
U-1179
8399450Nov 20, 2027in 1 yr 5 mo
SubstanceProduct
7964592Apr 29, 2028in 1 yr 11 mo
SubstanceProduct
8039479Jun 29, 2030in 4 yr 1 mo
SubstanceProduct
9309229Jan 18, 2032in 5 yr 8 mo
SubstanceProduct
8703787Feb 02, 2032in 5 yr 8 mo
U-1179
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.